AS07 Insulin Pumps

251 - REGULAR USERS OF TEMPORARY BASAL RATE OR EXTENDED BOLUS HAVE BETTER GLYCEMIC OUTCOMES IN 11,977 OMNIPOD INSULIN MANAGEMENT SYSTEM USERS WITH TYPE 1 DIABETES

Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Session Name
INSULIN PUMPS

Abstract

Background and Aims

Insulin pump features such as temporary basal rate and extended bolus (TBR/EB) provide people with diabetes the ability to customize their insulin therapy to meet their needs. This study retrospectively assessed glycemic outcomes stratified by frequency of TBR/EB use for a large cohort of people with T1D using the Omnipod® Insulin Management System (Insulet Corp., Acton, MA) with an integrated BG meter (Abbott Diabetes Care Inc., Alameda, CA) and data management system (Glooko, Mountain View, CA).

Methods

Insulin pump data uploaded to the data management system from February-August 2019 were matched via device serial number to a second database of self-reported demographic data and de-identified. Data from ≥3mo of system use per user were analyzed. Within each age group (<6y, 6-12.99y, 13-17.99y, 18-25.99y, 26-49.99y, and 50y), Glucose Management Indicator (GMI) was calculated based on 14 days of BG meter readings for those users who regularly (3.33% of days with gaps <60 days, 3mo of use) and infrequently (<3.33% of days) used TBR/EB.

Results

Of 11,977 users with T1D, there were 6,448 regular users and 4,908 infrequent users of TBR/EB. In each age group, GMI was significantly lower for regular users of TBR/EB than infrequent users (p<0.001). The number of users per age group and the GMI with regular or infrequent TBR/EB use are shown in the Figure.

Conclusions

While we cannot determine causation, regular users of TBR/EB have better glycemic outcomes than infrequent users. These real-world data support the training of people with T1D and caregivers on the effective use of these features.

glooko advanced features figure-01.png

Hide